Henderson, Nevada - May 25, 2006 - Emergency Filtration Products, Inc., (EFP) (OTCBB: EMFP) today reported that it had received
results from an established, BSL-3 (Bio - Safety Level 3) independent testing laboratory that a custom-engineered nanomaterial
formulation, licensed to EFP, completely inactivated the H9N2 strain of avian influenza within one minute. The Virucidal Efficacy
Test involved a titer of virus with a concentration greater than 6 logs.

"The virus tested was of a higher concentration than typically used in this type of challenge," said Douglas K. Beplate, president
and CEO, EFP. "An expanded and ongoing testing program of this formulation, and possibly of additional custom-engineered
nanomaterials, will be conducted against H9N2 and other pathogens in the coming months."

About Emergency Filtration Products, Inc.:

EFP is an air filtration products manufacturer who's patented 2H Technology™ filter system has produced filtration efficiencies
of 'greater than 99.99%' at a particulate size of 0.027 microns. EFP's initial products were developed for the medical market:
the Vapor Isolation Valve™ and RespAide® CPR Isolation Mask used for resuscitation of respiratory/cardiac arrest cases; and
2H Breathing Circuit Filter for ventilators, respirators and anesthesia circuitry. Each has received FDA approval. The Company
also markets an Automated External Defibrillator Prep Kit featuring RespAide; and the NanoMask®, a nanotechnology enhanced
environmental mask. In addition to filtration products, the company supplies Superstat®, a modified hemostatic collagen, to the
U.S. Military for surgery and extreme wound care.

Safe Harbor Statement:

This release may contain statements that are forward looking. Such statements are made based upon current expectations that
are subject to risk and uncertainty. EFP does not undertake to update forward-looking statements in this news release to reflect
actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. The actual
future results of the company could differ significantly from such forward-looking statements. Specifically, successful production
of the NanoMask products may not translate into significant sales. Sales may be dependent on the success of future marketing
campaigns, the signing of definitive agreements with additional distributors, and both the perceived need for EFP's products and
the competitive performance of such products in the marketplace.

For Further Information on EFP:

Emergency Filtration Products:
Phone: 702/558-5164
Fax: 702/567-1893
Email: contactus@emergencyfiltration.com
Web: www.emergencyfiltration.com

or
Investor Relations:
WPH Consultants Ltd.
Philippe Niemetz
Phone: 800/477-7570, 212/344-6464
Fax: 212/509-2755
Email: philippe.niemetz@wphconsultants.com